BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units to six newly hired employees covering an aggregate of 61,750 shares, effective May 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units to six newly hired employees covering an aggregate of 61,750 shares, effective May 1, 2026.
The RSUs were issued under Nasdaq Listing Rule 5635(c)(4), vest in four equal annual installments beginning on the one-year anniversary, and are subject to the Inducement Equity Incentive Plan and individual RSU agreements.
Details
News Market Reaction – BCRX
On May 5, the day this news came out, BCRX closed 1.85% below the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- New hire count
- 6 employees
- Newly-hired employees receiving inducement RSUs
- Inducement RSUs
- 61,750 shares
- Aggregate RSUs granted as of May 1, 2026
- Grant date
- May 1, 2026
- RSU grant date for inducement awards
- Vesting schedule
- 4 equal annual installments
- RSUs vest over four years, starting one year after grant
Historical Context
-
European license for navenibart with upfront, milestone payments and royalties.
-
Investors informed of May and June 2026 healthcare conference presentations.
-
Announcement of timing for first quarter 2026 results and conference call.
-
Hiring of new Chief R&D Officer linked to pipeline and launch preparation.
-
Prior inducement RSUs of 65,850 shares to six new employees under Rule 5635(c)(4).
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.